human genome sciences inc
- Human Genome Sciences Inc., which was acquired for $3.6 billion by London-based GlaxoSmithKline Plc in August, intends to lay off 97 employees in mid-December, and an additional but unspecified number of cuts are planned for next year, the company warned Maryland labor regulators this week.
- Rockville-based Human Genome Sciences warned state regulators that it plans to cut 114 jobs beginning in October, three months after striking a deal to be acquired by GlaxoSmithKline.
- Human Genome, which uses the human DNA sequence to develop targeted drugs, was able to raise its price to $14.25 for sale to London-based GlaxoSmithKline Plc, valuing the company at $3.6 billion. In April, GlaxoSmithKline offered to buy Human Genome for $13 a share, or $2.6 billion.
- Human Genome ultimately rebuffed a $2.6 billion offer by biopharmaceutical giant GlaxoSmithKline Plc, saying it was too low – though it has put itself on the market. Catalyst agreed to be acquired by a larger Illinois competitor for $4.4 billion.
- Shares of Human Genome Sciences doubled in Thursday morning trading on news it received a $2.6 billion cash offer to acquire the company from a major bio pharmaceutical company, which it rejected as too low.
- Maryland officials are pitching the state's talent pool —corporate executives, academics and consultants that regularly deal with the federal government — as a resource for supporting existing companies and attracting new ones.